On December 10, 2025 Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") reported it will present data on potential treatments for pancreatic and gastric/gastroesophageal junction (G/GEJ) cancer at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal (GI) Cancers Symposium taking place January 8-10, 2026 in San Francisco, California. Highlights include a late-breaking oral presentation of cohort results from the Phase 2 ILUSTRO study of first-line zolbetuximab in combination with chemotherapy and immunotherapy in claudin 18.2-positive, HER2-negative, locally advanced or metastatic G/GEJ cancer, as well as new Phase 1 data from ASP3082 (setidegrasib), an investigational KRAS G12D targeted protein degrader, in pancreatic cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Moitreyee Chatterjee-Kishore, Ph.D., M.B.A., Head of Oncology Development, Astellas
"At Astellas, we are harnessing next-generation treatment modalities and a precision biomarker-driven approach to deliver treatments that make a meaningful difference for patients with gastrointestinal cancers. We’re excited to share data at ASCO (Free ASCO Whitepaper) GI from our growing portfolio of assets in GI cancers – which showcase our commitment to better understanding how to treat these diseases – including emerging data from zolbetuximab as well as progress on ASP3082 (setidegrasib), our investigational KRAS G12D targeted protein degrader. Together with the passionate GI cancer community of patients, physicians, and advocates, we are working to transform outcomes for patients and pave the future of cancer care."
Astellas Presentations at ASCO (Free ASCO Whitepaper) GI 2026
Zolbetuximab
Presentation Title
Presenter
Presentation Details
Phase 2 ILUSTRO trial of first-line
zolbetuximab plus mFOLFOX6 and
nivolumab in patients with claudin
18 isoform 2-positive, human
epidermal growth factor receptor 2-
negative, locally advanced or
metastatic gastric or
gastroesophageal junction
adenocarcinoma
K. Shitara
Type: Oral presentation
Abstract Number: LBA284
Date: January 8, 2026,
8:47 a.m. – 8:57 a.m. PST
Determinants of biomarker testing
and treatment selection by
oncologists caring for patients with
gastric or gastroesophageal
junction adenocarcinoma
R. Fuldeore
Type: Poster
Abstract Number: 453
Date: January 8, 2026,
11:30 a.m. – 1:00 p.m.;
6:00 p.m. – 7:00 p.m. PST
Zolbetuximab + pembrolizumab
and chemotherapy as first-line
treatment for patients with
CLDN18.2-positive, HER2-
negative, PD-L1-positive locally
advanced unresectable or
metastatic G/GEJ
adenocarcinoma: Phase 3, double-
blind, randomized trial (LUCERNA)
K. Shitara
Type: Poster
Abstract Number: TPS473
Date: January 8, 2026,
11:30 a.m. – 1:00 p.m.;
6:00 p.m. – 7:00 p.m. PST
Assessment of the impact of proton
pump inhibitor exposure on
survival outcomes in patients with
gastric or gastroesophageal
junction adenocarcinoma treated
with zolbetuximab plus
chemotherapy
A. Yamada
Type: Poster
Abstract Number: 349
Date: January 8, 2026,
11:30 a.m. – 1:00 p.m.;
6:00 p.m. – 7:00 p.m. PST
A real-world study of claudin 18.2
association with molecular
subtypes, mutations/biomarkers,
immune landscapes, and gene
signatures and prognostic value in
pancreatic ductal adenocarcinoma
G. Zhang
Type: Poster
Abstract Number: 744
Date: January 9, 2026,
11:30 a.m. – 1:00 p.m.;
5:00 p.m. – 6:00 p.m. PST
Treatment patterns and outcomes
of patients diagnosed with
metastatic pancreatic
adenocarcinoma
R. Fuldeore
Type: Poster
Abstract Number: 685
Date: January 9, 2026,
11:30 a.m. – 1:00 p.m.;
5:00 p.m. – 6:00 p.m. PST
ASP3082 (setidegrasib)
Presentation Title
Presenter
Presentation Details
Efficacy and safety of setidegrasib
(ASP3082) monotherapy or in
combination with mFOLFIRINOX in
patients with pancreatic ductal
adenocarcinoma
A. Kasi
Type: Poster
Abstract Number: 704
Date: January 9, 2026,
11:30 a.m. – 1:00 p.m.;
5:00 p.m. – 6:00 p.m. PST
Phase 1 evaluation of setidegrasib
(ASP3082), a first-in-class selective
protein degrader, in patients with
KRAS G12D-mutant pancreatic
ductal adenocarcinoma:
Pharmacokinetics and biomarker
insights
W. Park
Type: Poster
Abstract Number: 775
Date: January 9, 2026,
11:30 a.m. – 1:00 p.m.;
5:00 p.m. – 6:00 p.m. PST
(Press release, Astellas, DEC 10, 2025, View Source [SID1234661353])